Martin Shkreli

Tommy the Hamburger is here again, and this is Historical Depravity, where we dig up the polished bones of history, crack them open, and show you the rot they tried to dress up as greatness. They called these people kings, visionaries, captains of industry, patriots, reformers, whatever flattering bullshit helped the blood dry faster. I'm here to show you what they actually were. Martin Shkreli gets protected by a particularly modern kind of rot: the asshole genius myth. In that version, he is the obnoxious but brilliant provocateur who merely said the quiet part out loud about pharmaceutical pricing, a troll in a suit exposing the hypocrisy of an already corrupt industry. Maybe he was greedy, maybe he was smug, maybe he enjoyed the outrage too much, but the clean story says he was just one hypervisible jerk inside a system that would have done the same thing anyway. That version lets him keep too much dignity. Shkreli was not just a troll or an overhonest market ghoul. He was a hostage taker in a healthcare system, a man who looked at a lifesaving or life preserving drug with little market competition and saw leverage. Daraprim was not his invention. It was his opportunity. He acquired control over access and then used that control to squeeze money out of vulnerability. That is not innovation. That is extortion with a spreadsheet. The myth says blunt truth teller. Reality says a predator who found an exposed throat and started billing by the squeeze. And yes, the larger pharmaceutical system was already filthy. That matters. But it matters in the exact opposite way his defenders want. It does not soften him. It helps explain why he could act so openly. Shkreli was one of those American bastards who becomes famous by embodying a structure more nakedly than other people dare. He did not invent the logic that turns medicine into an asset class. He just stripped off the polite language and grinned while running the numbers. Fuck me sideways, if a patient needs a drug to avoid catastrophic illness and you jack the price into the stratosphere because the market lets you, then the market is not your defense. It is your weapon. Daraprim was used to treat toxoplasmosis, a severe parasitic infection especially dangerous for immunocompromised patients, including people with AIDS, and hazardous in pregnancy. This was not some vanity pill, not some luxury molecule for rich hypochondriacs, not some optional convenience product. It was a known drug with a known place in treatment. Shkreli looked at that existing medical dependency and realized it could be monetized brutally. The overnight price increase was not a side effect of research cost or development risk. It was the whole point. And that distinction matters because industry defenders love to drown this story in pharma jargon. They start waving around innovation incentives, orphan drug frameworks, capital recovery, research pipelines, shareholder duties, all the usual antiseptic sludge meant to turn stomach turning conduct into a difficult policy discussion. But Daraprim was old. The extraordinary price jump was not the price of invention. It was the price of capture. He bought a chokepoint. That chokepoint logic is exactly why he belongs here. He figured out that in American healthcare, if you can control access to something medically necessary and thinly substitutable, you can force hospitals, insurers, and patients into grotesque calculations. Every delay hurts. Every search for alternatives costs time. Every uncertainty lands on a sick body. That is how market power turns into intimate violence without ever firing a gun. And Shkreli made the whole thing even dirtier by enjoying the spectacle. Plenty of elite predators hide behind consultant language and lawyers. He smirked. He performed contempt. He framed the move as savvy, rational, and even virtuous in some warped market sense. That public posture matters because it revealed the moral logic underneath the business decision. There was no serious sign of conflict between his enrichment and the patient harm. The harm was simply accepted as collateral while he posed as the smartest guy in the room. That pose is one reason people still misread him. They think the real story is that he was too openly monstrous. No. The real story is that he was openly monstrous in a system that had already trained everyone to translate monstrosity into pricing strategy. His vulgarity made him easier to hate, but the actual mechanism was perfectly legible to plenty of respectable people in finance and pharma long before he became a meme villain. The victims here were not abstractions in an economics seminar. They were immunocompromised patients facing infections that could maim or kill. They were clinicians and hospitals suddenly forced to navigate absurd cost spikes around a known therapy. They were families discovering that one man's trade could push a standard treatment toward unaffordability or institutional rationing. They were people learning, yet again, that the American healthcare system does not merely fail the sick by accident. It often prices them as targets. And you have to stay on that point because this is where people start trying to get cute. They say insurers could negotiate. They say hospitals had workarounds. They say patient assistance programs existed. They say list price is not always final price. Fine. None of that changes the moral center. Once the owner of a medically necessary product spikes the price to exploit dependency, the violence is already present. Every subsequent workaround is just other people scrambling to contain the damage he chose to create. That scramble is part of the crime too. It eats clinical time, pharmacy time, hospital budgets, family attention, and plain human hope. Doctors stop thinking only about what works best and start thinking about what can still be obtained under extortion conditions. Patients stop being treated as people with urgent needs and start becoming bargaining chips inside reimbursement games. That is how a legal pricing maneuver becomes one more form of organized degradation. That is another reason the just following market rules excuse is garbage. Market rules are not weather. They are structured permissions. If the law and commercial culture allow someone to acquire an old drug and weaponize scarcity against vulnerable patients, then the law is dirty too. But the man who chooses to pull the trigger on that permission does not become less responsible because the chamber was legally loaded. Shkreli also matters because he exposed the lie that healthcare profiteering still depends on subtlety. He showed that a person could be brazen about life and death extraction and still remain, for a while, within the recognizable grammar of ordinary American business success. Investors, media, and public discourse had already normalized enough cruelty that his conduct could be discussed as provocative entrepreneurship instead of what it really was: ransom logic applied to medicine. And the aftermath sharpened the obscenity. His eventual criminal case centered on securities fraud, not on the core moral injury that made him notorious. That is incredibly American. The state cared most clearly when investor side lying and fund misuse came into view, not when a sick population got used as leverage. That does not mean securities fraud is nothing. It means the system's priorities were exposed all over again. Hurt capital one way and the law wakes up differently than when you hurt patients through pricing power. That is why he cannot be reduced to a meme era villain or a pharma clown footnote. He stands at the intersection of finance logic, healthcare scarcity, and public sadism. He became memorable because he was loud, but his loudness was not the main crime. The main crime was seeing medicine as a hostage asset and acting accordingly. And his notoriety performed one more ugly service for the system. By turning Shkreli into the face of pharma villainy, the broader industry got to act like he was some special contamination rather than a loud, concentrated sample. The cameras lingered on his smirk and missed the thousands of quieter boardrooms where the same basic logic kept humming: find dependency, secure exclusivity, push the price, and let the sick absorb the shock. The man of his industry defense fails too, even though the industry was and is packed with predatory pricing, patent games, market exclusivity abuse, and all kinds of extraction filth. Yes, pharma already had mountains of blood on its shoes. Yes, Shkreli was not alone in discovering that sick people make excellent captives. But he still chose this exact move, this exact price shock, this exact public sneer, this exact revelation of appetite. Industry context explains the room. It does not absolve the bastard grinning at the table. His defenders sometimes try the contrarian line that he was useful because he made everyone confront a broken system. That argument is morally diseased. A predator does not become a public educator because his abuse is so flamboyant that it briefly embarrasses the rest of the class. If anything, the attention he drew showed how many quieter versions of the same logic had already been normalized. He was not cleansing the system by embodying it. He was proving how comfortable the system had become with human need as leverage. He also exposed how neatly American institutions separate investor injury from patient injury. A securities offense looked legible. Drug extortion still got talked about like policy controversy. That split is part of the depravity too. And the legacy laundering is still gross. People remember the trolling, the online antics, the swagger, the Wu Tang album stunt, the congressional smirk. All that spectacle creates a weird distortion where personality starts overshadowing structure. But the structure is the point. The structure let one man take control over access to a longstanding essential drug and slam the price upward because patients and providers were trapped. Everything else is garnish on top of that obscenity. So file Martin Shkreli correctly. File him not as an abrasive truth teller or a misunderstood market realist, but as a price gouging hostage taker who treated illness as bargaining power. File Daraprim not as a case study in controversial pricing but as a perfect receipt for how American healthcare lets finance minded predators weaponize dependence. File the market rhetoric as camouflage. File the public sneer as evidence that he understood exactly what kind of pain he was monetizing and did not give a shit. And file the legacy myth where it belongs: in the same rotten cabinet as every other story that asks you to admire the honesty of a man who tells you, plainly, that he is robbing the sick. Shkreli was not brave for making the industry's cruelty more visible. He was one of its purest expressions, a loud little ghoul who showed that in the right American market, even an old lifesaving drug can be turned into a hostage note. That is the depravity on record. The myth is smaller now, the stink is stronger, and the body count is still the body count. See you in the next grave I have to dig up.